Objective To explore the application effect of extended care during the immunotherapy period with atezolizumab for postoperative non-small cell lung cancer patients. Methods This study was a randomized controlled trial. According to the random number table method, 102 non-small cell lung cancer patients who visited Henan Cancer Hospital from March 2019 to March 2022 were divided into a control group (51 cases) and an observation group (51 cases). There were 30 males and 21 females in the control group, aged (62.39±5.16) years, 3 cases in stage Ⅱ, 29 cases in stage Ⅲ, and 19 cases in stage Ⅳ. There were 31 males and 20 females in the observation group, aged (62.47±5.22) years, 2 cases in stage Ⅱ, 31 cases in stage Ⅲ, and 18 cases in stage Ⅳ. Both groups were treated with cisplatin combined with attillizumab for 4 consecutive courses of treatment with 3 weeks as 1 course. During the treatment period, routine care was given to the control group, while extended care was given to the observation group on the basis of the control group. The compliance behaviors, quality of life and psychological status before and after intervention, and nursing satisfaction were compared between the two groups. t test and χ2 test were used. Results The proportions of the patients in the control group who took medication as prescribed, persisted in exercise, had a reasonable diet, and had good emotions [70.59% (36/51), 68.63% (35/51), 64.71% (33/51), and 66.67% (34/51)] were lower than those in observation group [94.12% (48/51), 88.24% (45/51), 90.20% (46/51), and 92.16% (47/51)], with statistically significant differences (χ2=9.714, 5.795, 9.487, and 10.134, P=0.002, 0.016, 0.002, and 0.001). After intervention, the scores of physical function, sleep quality, emotional function, cognitive function, social function, and role function in both groups were higher than those before intervention, and those in the observation group [(75.69±4.13) points, (72.88±3.87) points, (71.33±4.57) points, (70.82±5.03) points, (72.77±4.66) points, and (77.17±3.89) points] were higher than those in the control group [(64.94±4.82) points, (63.72±3.96) points, (63.49±4.25) points, (62.49±5.17) points, (64.49±5.12) points, and (66.38±3.94) points], with statistically significant differences (all P<0.05). After intervention, the scores of anxiety, depression, and psychosis in both groups were lower than those before intervention, and those in the observation group [(1.36±0.32) points, (1.32±0.31) points, and (1.14±0.29) points] were lower than those in the control group [(1.73±0.38) points, (1.69±0.33) points, and (1.59±0.36) points], with statistically significant differences (all P<0.05). The overall nursing satisfaction in the observation group was higher than that in the control group [96.08% (49/51) vs. 82.35% (42/51)] (χ2=4.993, P=0.025). Conclusion Extended care has a definite effect during the postoperative atezolizumab immunotherapy period for non-small cell lung cancer, which can effectively improve the patients' quality of life and psychological status, enhance their compliance behaviors and nursing satisfaction.